Switzerland Prof Dr Jürg Utzinger of the Swiss Tropical and Public Health Institute (Swiss TPH) outlines the organisation’s important role within the global health landscape, how Switzerland collaborates with low- and middle-income countries, the growing significance of data, and what lessons can be taken from the COVID-19 crisis. In a…
Belgium The new Belgian government has moved to streamline its response to the COVID-19 crisis with the appointment of Pedro Facon, director general for health at Belgium’s Federal Public Service Health (FPSH) as ‘Corona Commissioner.’ In his novel new role, Facon will attempt to coordinate Belgium’s complex web of political…
Canada As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the concept of ‘national pharmacare’ for a number of years now, with fierce advocates on both sides of the debate. Canada [has] some of the…
Global Dr Muhammad Ali Pate, Global Director for Health, Nutrition and Population at the World Bank as well as Director of the Global Financing Facility for Women, Children and Adolescents, reflects on the impact of the current COVID-19 pandemic on the work that the global institution has been doing to promote…
Europe A selection of data on the Nordic pharma markets (Denmark, Finland, Iceland, Norway, and Sweden), including market value, R&D spend, production, exports and imports, employment, generics penetration, and healthcare spending based on 2020 data from the EFPIA. Sweden is the largest pharma market in the region, boasting a market…
USA In recent years the US has seen an overall decease in cancer deaths thanks to innovative medicines and treatments. However, much work remains to be done in targeting and eliminating cancers. Below we highlight data for cancer deaths and cases in the US per male and female populations. …
USA Dr Gerard Anderson of Johns Hopkins University Bloomberg School of Public Health critiques the US response to the COVID-19 pandemic, before explaining how access and affordability in the US can be improved, and his outlook on the future of American public health. To some extent, we are the poster…
Long Read Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most of whom seemed more intent on chasing demand in the decidedly more populous Asian market space. But, with an estimated annual growth rate of 10 percent,…
USA So far in 2020 PharmaBoardroom has conducted interviews with several key stakeholders in US healthcare. We have heard from leaders the US FDA, as well as representatives of patient groups, health insurance providers, and firms operating in the US on what they consider the most pressing issues facing US healthcare.…
USA US healthcare is often seen as a fragmented system of contrasts. The country has the highest healthcare expenditures as a percentage of GDP and the highest drug prices in the OECD, supporting the largest and most innovative healthcare market globally. However, it also has shockingly subpar healthcare outcomes compared to…
Belgium Sabena Solomon, general manager of GSK Benelux, speaks about her first impressions of the Belgium market, having come from GSK Finland, and her initial priorities for leading the affiliate. Solomon goes on to explain GSK’s continued commitment to ensuring patients have access to innovative medicines, the role the company plays…
UAE One year after King’s College Hospital’s establishment in the UAE, CEO Christian Schuhmacher discusses the hospital’s unique approach of combining the best of British healthcare with UAE’s superior services. He discusses why Dubai is an attractive destination for medical tourism, the benefits of patient pathway guidelines and where he hopes…
See our Cookie Privacy Policy Here